Opus Genetics, Inc. Form 8-K Summary
Business Context and Reporting Period
Opus Genetics, Inc. (IRD) filed this Current Report on Form 8-K on September 11, 2026. The filing addresses a revision to a data presentation initially issued on September 9, 2026, regarding clinical data from Cohort 1 of the Company's Phase 1/2 clinical trial of OPGx-BEST1 for patients with BEST1-related retinal diseases.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The document is a regulatory disclosure regarding clinical trial data corrections.
Material Changes
The filing corrects an immaterial error in the translation of logMAR visual acuity into ETDRS letters found in the original September 9, 2026 presentation. The correction impacts the depiction of mean best-corrected visual acuity from baseline through 3 months on Slide 15. The corrected three-month change from baseline for specific participants is as follows:
- 101-101: 12 letter improvement (treated eye), 4 letter improvement (fellow eye).
- 101-104: 1 letter improvement (treated eye), 7 letter loss (fellow eye).
- 102-101: 10 letter loss (treated eye), 8 letter loss (fellow eye).
- 102-102: 2 letter gain (treated eye), 5 letter loss (fellow eye).
- 101-106: 6 letter gain (treated eye), 2 letter gain (fellow eye).
Additionally, high-resolution images of microperimetry grids for baseline and 3 months were added to the Appendix of the revised presentation.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. It does not disclose new risks or contingencies beyond the correction of the previously reported clinical data.
Investor Verification Checklist
- Verify the corrected visual acuity data in the revised data presentation (Exhibit 99.1) compared to the original September 9, 2026 filing.
- Review the newly added high-resolution microperimetry grid images in the Appendix for individual loci data.
- Confirm that the error was classified as immaterial by the Company.